Andreas Koeberle is a full professor and head of the Pharmacognosy section at the University of Graz. He holds a degree in biochemistry and earned his Ph.D. in Medicinal Chemistry/Analytics from the University of Tuebingen, Germany, in 2009. Following postdoctoral research at the University of Tokyo, Japan, he joined the University of Jena as junior group leader and established the institutional lipidomics facility within the Chair of Medicinal/Pharmaceutical Chemistry. In 2018, he was appointed visiting professor at the University of Vienna, and, in 2019, he accepted a full professorship for New Phyto Entities at the University of Innsbruck, where he established and led the Michael Popp Institute until 2024. His research has been funded by the Austrian Science Fund (FWF), German Research Foundation (DFG), Phospholipid Research Center (PRC), Michael A. Popp Nature Science Foundation, and industrial collaborations and has been honored by several national and international awards. Currently, he focuses on the mechanistic links between lipid metabolism and lipid signaling at the crossroads of inflammation, cancer, and cellular homeostasis, with special emphasis on identifying innovative drug targets and biogenic lead compounds in programmed cell death (ferroptosis) and the resolution of inflammation.